| Identification | Back Directory | [Name]
trabodenoson | [CAS]
871108-05-3 | [Synonyms]
PJ 875
INO-8875
INNO-8875
trabodenoson
N-Cyclopentyladenosine 5'-nitrate
Adenosine, N-cyclopentyl-, 5'-nitrate
((2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)METHYL NITRATE | [Molecular Formula]
C15H20N6O6 | [MDL Number]
MFCD28502082 | [MOL File]
871108-05-3.mol | [Molecular Weight]
380.36 |
| Chemical Properties | Back Directory | [Boiling point ]
691.2±65.0 °C(Predicted) | [density ]
1.87±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO: soluble | [form ]
A crystalline solid | [pka]
12.99±0.70(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
Trabodenoson alters ECM turnover by TM cells and increases conventional outflow facility, which accounts for its ability to lower IOP in young and aged mice. | [in vivo]
Trabodenoson (6.0%), demonstrating an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation)[1].
Topical trabodenoson significantly upregulates nestin expression in the ONH of induced eyes compared with vehicle-treated no-induced eyes[2].
Trabodenoson-treated eyes have significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. RGC counts are higher in Trabodenoson-treated eyes compared to vehicle (74% versus 47% of the contralateral eye)[2].
| Animal Model: | Young (3-4 months old) and aged (12 months old)[1]. | | Dosage: | 3% or 6% in 10 μL. | | Administration: | Eye drop for 7 consecutive days. | | Result: | Decreased IOP. |
| Animal Model: | Rats[2]. | | Dosage: | 3%. | | Administration: | Topical delivery daily. | | Result: | Had significantly reduced optic nerve (ON) edema. |
|
|
| Company Name: |
Wuhan Topule
|
| Tel: |
+86-02787215551 +86-19945035818 |
| Website: |
http://www.topule.com/ |
|